Inorg Chem:药+金属离子 = 抗癌

2016-02-19 佚名 生物谷

目前,抵御化疗耐药性的癌症对于科学家们来讲依然还是一项巨大挑战,而一种利用两组化合物配对的新型方法或许可以表现出特殊的抗癌特性,近日刊登在国际杂志Inorganic Chemistry上的一篇研究报告中,科学家们就利用疼痛药物结合金属离子进行结合,在实验室中成功地破坏了药物耐受性癌细胞,同时还保

目前,抵御化疗耐药性的癌症对于科学家们来讲依然还是一项巨大挑战,而一种利用两组化合物配对的新型方法或许可以表现出特殊的抗癌特性,近日刊登在国际杂志Inorganic Chemistry上的一篇研究报告中,科学家们就利用疼痛药物结合金属离子进行结合,在实验室中成功地破坏了药物耐受性癌细胞,同时还保证了正常细胞不受损伤。

长期以来研究者们经常会在癌症药物中配合使用金属离子,比如顺铂就是一种基于铂的抗癌疗法,其在抵御肺癌、卵巢癌及其它癌症上已经使用了很多年了,但通常癌细胞都会产生一定的耐药性。

然而最近研究者们却利用金属离子和药物的组合来开发破坏癌细胞的新型疗法,不同于基于铂的络合物,金属络合物会表现出一定的抗癌潜能,而且很多研究都发现非甾体类的抗炎药(nonsteroidal anti-inflammatory drugs, NSAIDs)可以有效抵御特定的癌症,并且增强其它药物的作用活性。文章中研究者Paul J. Dyson就与同事决定将非甾体类的抗炎药吲哚美辛同携带钌和锇离子的双氯芬酸进行结合来观察这种组合是否具有异性的抗癌效能。

研究人员创造了多种不同的NSAID-金属离子复合物组合,随后在实验室中检测其抵御癌症的潜力,结果显示,相比顺铂而言有些组合可以更加有效地抵御卵巢癌细胞,而且相比较健康细胞而言,有些组合对顺铂耐药的癌细胞而言具有较强的毒性作用,本文研究或对于后期开发新型的药物组合来彻底抵御癌症提供了新的线索。

原始出处:

EmiliaPaunescu,SarahMcArthur,MylèneSoudani,etal.NonsteroidalAnti-inflammatory—OrganometallicAnticancerCompounds.Inorganic Chemistry,2016,55(4):1788–1808.doi:10.1021/acs.inorgchem.5b02690

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=298389, encodeId=448e2983890b, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Mar 21 21:11:42 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=65085, encodeId=b5a565085e1, content=Medsci经常不能加载更新数据,为什么?, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134a1674389, createdName=1de1c0aem76(暂无匿称), createdTime=Sun Feb 21 16:49:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64976, encodeId=6b00649e666, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Sat Feb 20 20:03:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64963, encodeId=cee064963db, content=知了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Feb 20 18:12:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64907, encodeId=32d76490ec7, content=NSAIDs有抗癌活性get, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a701654185, createdName=雏菊, createdTime=Sat Feb 20 15:54:00 CST 2016, time=2016-02-20, status=1, ipAttribution=)]
    2018-03-21 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=298389, encodeId=448e2983890b, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Mar 21 21:11:42 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=65085, encodeId=b5a565085e1, content=Medsci经常不能加载更新数据,为什么?, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134a1674389, createdName=1de1c0aem76(暂无匿称), createdTime=Sun Feb 21 16:49:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64976, encodeId=6b00649e666, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Sat Feb 20 20:03:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64963, encodeId=cee064963db, content=知了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Feb 20 18:12:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64907, encodeId=32d76490ec7, content=NSAIDs有抗癌活性get, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a701654185, createdName=雏菊, createdTime=Sat Feb 20 15:54:00 CST 2016, time=2016-02-20, status=1, ipAttribution=)]
    2016-02-21 1de1c0aem76(暂无匿称)

    Medsci经常不能加载更新数据,为什么?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=298389, encodeId=448e2983890b, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Mar 21 21:11:42 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=65085, encodeId=b5a565085e1, content=Medsci经常不能加载更新数据,为什么?, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134a1674389, createdName=1de1c0aem76(暂无匿称), createdTime=Sun Feb 21 16:49:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64976, encodeId=6b00649e666, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Sat Feb 20 20:03:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64963, encodeId=cee064963db, content=知了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Feb 20 18:12:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64907, encodeId=32d76490ec7, content=NSAIDs有抗癌活性get, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a701654185, createdName=雏菊, createdTime=Sat Feb 20 15:54:00 CST 2016, time=2016-02-20, status=1, ipAttribution=)]
    2016-02-20 stupidox

    有意思

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=298389, encodeId=448e2983890b, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Mar 21 21:11:42 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=65085, encodeId=b5a565085e1, content=Medsci经常不能加载更新数据,为什么?, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134a1674389, createdName=1de1c0aem76(暂无匿称), createdTime=Sun Feb 21 16:49:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64976, encodeId=6b00649e666, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Sat Feb 20 20:03:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64963, encodeId=cee064963db, content=知了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Feb 20 18:12:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64907, encodeId=32d76490ec7, content=NSAIDs有抗癌活性get, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a701654185, createdName=雏菊, createdTime=Sat Feb 20 15:54:00 CST 2016, time=2016-02-20, status=1, ipAttribution=)]
    2016-02-20 lyh994

    知了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=298389, encodeId=448e2983890b, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Mar 21 21:11:42 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=65085, encodeId=b5a565085e1, content=Medsci经常不能加载更新数据,为什么?, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134a1674389, createdName=1de1c0aem76(暂无匿称), createdTime=Sun Feb 21 16:49:00 CST 2016, time=2016-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64976, encodeId=6b00649e666, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Sat Feb 20 20:03:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64963, encodeId=cee064963db, content=知了, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Feb 20 18:12:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64907, encodeId=32d76490ec7, content=NSAIDs有抗癌活性get, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a701654185, createdName=雏菊, createdTime=Sat Feb 20 15:54:00 CST 2016, time=2016-02-20, status=1, ipAttribution=)]
    2016-02-20 雏菊

    NSAIDs有抗癌活性get

    0

相关威廉亚洲官网

科研转型,且转且探索

2015年诺贝尔生理或医学奖首次出现了中国人的身影,青蒿素发现者--屠哟哟教授的获奖引起了广泛探讨,中国在国际科研圈的影响力正显着提高。而近日Nature杂志公布的2015年度十大人物中,来自中山大学的生物学家黄军就和美国斯坦福大学华裔女科学家鲍哲楠也因各自在其专业领域的突出贡献再一次将全球目光聚焦于中国科研界。 中国在科研领域显着和持续的投入,已推动了国家科研产出的大幅增加。然而,中国科研的

PNAS:CRISPR-Cas9系统构建心脏衰竭小鼠模型

突变体小鼠模型为williamhill asia 研究个别基因对发育、生理以及疾病发生等科学问题提供了极大的便利。然而,传统的小鼠突变体模型构建是一项十分耗时耗力的工程。最近的CRISPR-Cas9系统对于动物体的遗传修饰是一项革命性的突破。 CRISPR系统首先被发现于细菌抗病毒侵染的免疫系统,通过一类sgRNA的介导,核酸内切酶Cas9能够被引导到特定的基因序列区域,Cas9的切割会造成基因的双链断裂,而在基因损伤修

深入剖析人体微生物加速健康改善

来自奥克拉荷马大学(University of Oklahoma)的人类学家目前正在研究古代和现代人类的微生物组学,而且微生物组在人类健康和疾病发生过程中发挥着重要作用;通过将基因组和蛋白质组测序技术应用于古代人类的微生物组研究中,比如粪化石和牙石等,研究人员就可以深入理解williamhill asia 机体微生物组的进化历史及其对当代人类健康的关系。 在近日的“美国科学促进协会小组进化生物学对当代医学和公共卫生的影响”会

Sci Rep:编辑干细胞疗法或可治疗失明

图片来源:medicalxpress.com 近日,刊登于国际杂志Scientific Reports上的一项研究论文中,来自哥伦比亚大学等处的研究人员利用CRISPR/Cas9基因编辑技术成功修正了患者机体干细胞中引发失明的基因突变,相关研究结果或为后期开发个体化治疗眼部疾病的新型疗法提供了新的线索。 研究者Alexander Bassuk说道,williamhill asia 的目的是修复X-连锁视网膜色素变性(X

新一代“腺病毒载体”凤凰涅磐,助力基因治疗

随着新技术的不断推出,腺病毒载体(Adenovectors)又热了起来。在基因医学(gene-based medicine)引发最初的兴奋20年后,研究人员和媒体又一次对该领域出现的一系列医学突破表现出了狂热之情。推动这一“复兴”的力量是大量技术的进步,比如CRISPR/Cas9和其它基因编辑技术的发展(TALEN、Zinc Finger和 ARCUS)。 这些基因编辑技术为研究人员修改基因

Lancet:暂未发现基因治疗心衰的有益证据(CUPID 2研究)

心衰患者中肌浆/内质网Ca2+ -ATP酶(SERCA2a)活性常缺乏。而对该基因进行基因移植可能会改善心功。研究者进行了一项研究,探究对心衰和射血分数下降的患者,进行冠状动脉内输注腺相关病毒1型(AAV1)/SERCA2a的临床有效性和安全性。该研究纳入了NYHA II–IV级的心衰患者和左室射血分数≤0·35的患者共计250名患者。按1:1随机分为试验组(123名)和对照组(127名)。试验组